Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EKSO vs ESAB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ESAB Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

ESAB Overall Winner 6-Pillar Tally: EKSO 0 – 5 ESAB (1 Tie) Matrix Metrics: EKSO 2 – 8 ESAB

As of Nov 20, 2026, ESAB Corporation (ESAB) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas ESAB carries 27.6/100 (SELL) at $74.74 (11.9x Forward P/E, 14.8% operating margin).

  • Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. ESAB 27.6/100 SELL), ESAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (14.8% vs. -119.7% operating margin) and revenue trajectory (+13.3% vs. -38.3% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EKSO vs ESAB
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65
ESAB NYSE Head-to-Head Winner
ESAB Corporation
General Industrial Machinery & Equipment, Nec
$74.74
-3.26% 1D
Market Cap $4.9B
TTM Revenue $3.10B
Forward P/E 11.9x
Beta / 30D Vol 1.77β · 63% Vol
Unified Composite Score
27.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.5 · SMA20: $78.10 · SMA50: $71.52

6-Pillar Scorecard Institutional Category Breakdown (EKSO 0 – 5 ESAB)

Columns: Metric · EKSO · ESAB
1. Valuation Multiples ESAB
Forward P/E N/M 11.9x
Trailing P/E N/M 28.2x
PEG Ratio N/M 0.80x
EV / Revenue 3.3x 1.6x
2. Growth & Scale ESAB
Revenue Growth (YoY) -38.3% +13.3%
Earnings Growth (YoY) +0.0% -35.6%
TTM Revenue (USD) $13M $3.10B
Market Cap $42.0M $4.9B
3. Profitability & Quality ESAB
Gross Margin 53.5% 37.6%
Operating Margin -119.7% 14.8%
Net Profit Margin -91.4% 5.1%
Return on Equity (ROE) -107.6% 7.6%
4. Balance Sheet & Cash Flow ESAB
Cash Generation (TTM) -$11M EBITDA $578M EBITDA
Cash Flow Margin -86.0% EBITDA Mgn 18.6% EBITDA Mgn
Net Cash / Leverage $2.54 Book/Sh · -107.6% ROE $38.42 Book/Sh · 7.6% ROE
Dividend Yield None (0.00%) 0.57%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 47.4% (18th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ESAB
OpEx & R&D Intensity N/A 22.8% of Rev ($707M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Metal Fabrication Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EKSO (2) vs ESAB (8)
Institutional Metric EKSO ESAB Criterion Row Edge
Market Capitalization
Scale
$42.0M $4.9B Larger Scale ESAB
Trailing P/E Ratio
Valuation
N/M 28.2x Lower Multiple ESAB
Forward P/E Ratio
Valuation
N/M 11.9x Lower Multiple ESAB
Revenue Growth (YoY)
Growth
-38.3% +13.3% Higher Growth ESAB
Operating Margin (TTM)
Profitability
-119.7% 14.8% Higher Margin ESAB
Net Profit Margin
Profitability
-91.4% 5.1% Higher Margin ESAB
Return on Equity (ROE)
Capital Efficiency
-107.6% 7.6% Higher ROE ESAB
52-Week Range Position
Momentum
87% ($0–$14) 16% ($63–$137) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
2.16β · 76% Vol 1.77β · 63% Vol Lower Realized Risk ESAB
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 27.6 / 100 (SELL) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$13M $3.10B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.5% 37.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev 0.80x PEG · 1.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) $578M EBITDA ($38.42 Book/Sh · 7.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +29.05 pp
EKSO: +25.53% · ESAB: -3.52%
3M Horizon EKSO +43.13 pp
EKSO: +25.93% · ESAB: -17.2%
6M Horizon EKSO +202.37 pp
EKSO: +192.8% · ESAB: -9.57%
1Y Horizon EKSO +202.37 pp
EKSO: +192.8% · ESAB: -9.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs ESAB. Trailing 12-month operating profitability (EKSO -119.7% vs ESAB 14.8%) and valuation multiples (EKSO N/M vs ESAB 11.9x Forward P/E) are benchmarked directly in Pillar 4 below.

EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M
ESAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.10B
Gross Margin37.6%
Op. Margin14.8%
ROE / Fwd P/E7.6% · 11.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ESAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 47.4%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ESAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ESAB Moat Profile Cyclical / Execution-Driven Positioning
Metal Fabrication Operator
Competes within the Metal Fabrication value chain with $4.9B market capitalization and 14.8% operating margin.
OpEx & R&D Reinvestment 22.8% of Rev ($707M)
90D Engineering Disclosures 0 Published

Investor FAQ EKSO vs ESAB Key Questions & Quantitative Answers

As of Nov 20, 2026, ESAB Corporation (ESAB) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas ESAB carries 27.6/100 (SELL) at $74.74 (11.9x Forward P/E, 14.8% operating margin). Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. ESAB 27.6/100 SELL), ESAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (14.8% vs. -119.7% operating margin) and revenue trajectory (+13.3% vs. -38.3% YoY).

ESAB leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with ESAB at +13.3% YoY revenue growth and -35.6% YoY earnings growth on $3.10B TTM revenue (37.6% gross margin, 14.8% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus $3.10B for ESAB. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus 22.8% of Rev ($707M) (0 disclosures) for ESAB.

ESAB screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas ESAB trades at 11.9x Forward P/E, 28.2x Trailing P/E, 0.80x PEG, and 1.6x EV/Revenue (18.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus ESAB (7.6% ROE) capital efficiency.

In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, ESAB carries 47.4% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.77β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.